See more : PT Hasnur Internasional Shipping Tbk (HAIS.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ningbo Menovo Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Uber Technologies, Inc. (UBER) Income Statement Analysis – Financial Results
- Iljin Display Co., Ltd. (020760.KS) Income Statement Analysis – Financial Results
- Beowulf Mining plc (BEM.L) Income Statement Analysis – Financial Results
- CaliPharms, Inc. (KGET) Income Statement Analysis – Financial Results
- Roscan Gold Corporation (RCGCF) Income Statement Analysis – Financial Results
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.menovopharm.com
About Ningbo Menovo Pharmaceutical Co., Ltd.
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. It offers APIs, intermediates, and formulations for the treatment of cardiovascular, central nervous, respiratory, antitumor, anti-infection, digestive, and geriatric diseases, as well as antiviral. The company was founded in 2004 and is headquartered in Ningbo, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.22B | 1.46B | 1.26B | 1.19B | 1.18B | 848.96M | 605.32M | 578.09M | 597.17M | 636.30M | 501.73M | 486.65M | 490.24M |
| Cost of Revenue | 873.79M | 872.80M | 788.93M | 758.57M | 727.63M | 572.50M | 399.07M | 361.51M | 400.47M | 426.15M | 329.11M | 326.23M | 331.59M |
| Gross Profit | 342.71M | 584.19M | 469.22M | 435.12M | 452.58M | 276.46M | 206.26M | 216.58M | 196.70M | 210.15M | 172.61M | 160.41M | 158.65M |
| Gross Profit Ratio | 28.17% | 40.10% | 37.29% | 36.45% | 38.35% | 32.56% | 34.07% | 37.46% | 32.94% | 33.03% | 34.40% | 32.96% | 32.36% |
| Research & Development | 95.30M | 98.16M | 88.31M | 62.05M | 52.96M | 39.21M | 32.02M | 29.08M | 38.12M | 30.55M | 22.60M | 25.98M | 0.00 |
| General & Administrative | 54.47M | 76.21M | 52.58M | 49.68M | 59.16M | 33.17M | 25.46M | 17.79M | 15.13M | 17.78M | 75.47M | 69.69M | 61.00M |
| Selling & Marketing | 51.44M | 50.62M | 29.29M | 14.34M | 21.33M | 18.87M | 17.30M | 12.95M | 12.95M | 13.44M | 9.30M | 8.61M | 8.92M |
| SG&A | 220.10M | 126.84M | 81.87M | 64.02M | 80.49M | 52.04M | 42.76M | 30.75M | 28.08M | 31.22M | 84.77M | 78.30M | 69.92M |
| Other Expenses | 8.57M | 116.38M | 110.82M | 109.91M | 102.79M | -5.80M | 489.82K | 11.51M | 10.26M | 2.91M | 5.43M | 2.21M | 2.04M |
| Operating Expenses | 323.96M | 341.37M | 281.00M | 235.98M | 236.24M | 171.25M | 131.61M | 117.56M | 119.56M | 108.99M | 87.80M | 80.07M | 71.45M |
| Cost & Expenses | 1.20B | 1.21B | 1.07B | 994.55M | 963.86M | 743.75M | 530.67M | 479.07M | 520.03M | 535.15M | 416.92M | 406.31M | 403.03M |
| Interest Income | 5.52M | 5.66M | 2.17M | 2.96M | 1.56M | 2.26M | 3.57M | 685.01K | 1.83M | 1.22M | 2.08M | 2.69M | -0.75 |
| Interest Expense | 29.98M | 27.45M | 27.17M | 26.20M | 23.38M | 19.62M | 4.39M | 2.68M | 1.60M | 8.08M | 0.00 | 0.00 | 3.85M |
| Depreciation & Amortization | 125.55M | 109.26M | 102.63M | 90.61M | 64.55M | 50.93M | 33.73M | 9.89M | 29.59M | 25.94M | -2.75M | 9.29M | -9.37M |
| EBITDA | 155.45M | 498.48M | 301.58M | 321.40M | 275.06M | 158.39M | 101.17M | 116.14M | 111.40M | 128.20M | 84.81M | 87.42M | 82.82M |
| EBITDA Ratio | 12.78% | 36.63% | 24.80% | 30.81% | 24.30% | 21.93% | 16.84% | 26.35% | 22.41% | 20.61% | 16.35% | 17.36% | 16.89% |
| Operating Income | 18.75M | 405.32M | 187.91M | 215.54M | 189.73M | 112.56M | 63.88M | 98.45M | 91.50M | 91.61M | 84.81M | 75.19M | 92.19M |
| Operating Income Ratio | 1.54% | 27.82% | 14.94% | 18.06% | 16.08% | 13.26% | 10.55% | 17.03% | 15.32% | 14.40% | 16.90% | 15.45% | 18.80% |
| Total Other Income/Expenses | -10.79M | -21.16M | -7.61M | -2.35M | -2.49M | -5.80M | 489.82K | 4.66M | 9.54M | 2.58M | 5.13M | -1.83M | 1.35M |
| Income Before Tax | 7.96M | 384.16M | 180.29M | 214.66M | 187.25M | 106.76M | 64.37M | 105.17M | 101.05M | 94.19M | 89.93M | 77.20M | 93.53M |
| Income Before Tax Ratio | 0.65% | 26.37% | 14.33% | 17.98% | 15.87% | 12.58% | 10.63% | 18.19% | 16.92% | 14.80% | 17.92% | 15.86% | 19.08% |
| Income Tax Expense | -8.22M | 16.55M | 22.22M | 41.61M | 26.45M | 1.70M | 14.42M | 20.05M | 19.28M | 15.69M | 16.27M | 12.84M | 14.82M |
| Net Income | 11.59M | 338.86M | 142.53M | 155.96M | 150.90M | 96.35M | 44.68M | 78.84M | 77.02M | 72.73M | 69.01M | 60.61M | 69.33M |
| Net Income Ratio | 0.95% | 23.26% | 11.33% | 13.07% | 12.79% | 11.35% | 7.38% | 13.64% | 12.90% | 11.43% | 13.75% | 12.45% | 14.14% |
| EPS | 0.05 | 1.61 | 0.69 | 0.76 | 0.75 | 0.48 | 0.24 | 0.52 | 0.51 | 0.48 | 0.46 | 0.40 | 0.64 |
| EPS Diluted | 0.05 | 1.49 | 0.66 | 0.76 | 0.73 | 0.47 | 0.24 | 0.52 | 0.51 | 0.48 | 0.46 | 0.40 | 0.64 |
| Weighted Avg Shares Out | 231.71M | 210.40M | 207.41M | 205.55M | 201.64M | 200.90M | 189.14M | 150.20M | 150.14M | 150.52M | 150.24M | 151.64M | 108.55M |
| Weighted Avg Shares Out (Dil) | 231.71M | 227.35M | 216.43M | 205.55M | 205.39M | 203.94M | 189.14M | 150.20M | 150.14M | 150.53M | 150.24M | 151.65M | 108.55M |
Source: https://incomestatements.info
Category: Stock Reports